

PerCP/Cy5.5 anti-human CD309 (VEGFR2)

Catalog # / Size: 2399540 / 100 tests
2399535 / 25 tests

Clone: 7D4-6

Isotype: Mouse IgG1, κ


Immunogen: Human KDR recombinant protein

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

Concentration: Lot-specific



HUVEC human endothelial cells were stained with CD309 (clone 7D4-6) PerCP/Cy5.5 (filled histogram) or mouse IgG1, κ PerCP/Cy5.5 isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cy5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Description: CD309, also known as VEGF-R2, KDR, and Flk-1 (mouse), is a type I transmembrane glycoprotein. It is a member of the CSF-1/PDGF receptor family of type III tyrosine kinase receptors. Human VEGF-R2 is mainly expressed by endothelial cells, embryonic tissues, and megakaryocytes. It plays an important role in the regulation of angiogenesis, vasculogenesis, and vascular permeability. The ligands of VEGF-R2 include VEGF-A, VEGF-C, and VEGF-D splice isoforms. Activation of VEGF-R2 with its ligands results in the receptor dimerization and autophosphorylation, stimulating endothelial cell proliferation and migration.

Antigen References:

1. Zola H, *et al.* 2007. Leukocyte and Stromal Cell Molecules: The CD Markers Wiley-Liss A John Wiley & Sons Inc, Publication.
2. Ferrara N and Gerber HP. 2002. *Acta. Haematol.* 106:148.
3. Murohara T, *et al.*